Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...

Adaptive Biotechnologies Corporation is rated Hold as MRD segment momentum offset by competitive & valuation concerns. Read ...

Chad Robins, CEO & Co-Founder, emphasized "another quarter of strong execution and accelerating momentum across the business," highlighting meaningful wins in profitability and growth for the MRD ...

The move will dilute the Seattle company's ownership in the subsidiary from 70% to less than 50%, according to the filing.

About 100 workers are being laid off as Adaptive Biotechnologies reorganizes its business, homing in on just two core areas of healthcare that can be served by its immune system-focused genetic ...

Adaptive Biotechnologies ( ($ADPT) ) has issued an announcement. On December 30, 2025, Adaptive Biotechnologies announced that its 70%-owned ...

Adaptive Biotechnologies (NASDAQ: ADPT), a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the ...

CEO Chad Robins highlighted a strong start to the year, with MRD revenue increasing 34% year-over-year, driven by clinical volumes, ASP improvements, and pharma sequencing. The company received its ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The market continued its ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. The commercial-stage Adaptive booked $58.9 ...

Adaptive Biotechnologies Co-founder and CEO Chad Robins speaking from the Health Tech stage at the 2018 GeekWire Summit. (GeekWire Photo / Kevin Lisota) Adaptive Biotechnologies announced its first ...

On a relatively sleepy day for the market, the biotech enjoyed a decent little price pop on earnings. Its first quarter results topped analyst estimates on both the top and bottom lines. A double beat ...